HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
HERON THERAPEUTICS, INC. /DE/
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$0.36−0.00 (-0.03%)
Close on Oct 19, 2026
- Market cap
- $68.69M
- P/E (TTM)
- –
- Dividend yield
- –
HERON THERAPEUTICS, INC. /DE/ revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| CINVANTI | $96.76M | $100.08M | $94.87M | $87.25M | $73.51M | $87.82M | $132.16M | $56.20M | 62.5% | -3.3% |
| ZYNRELEF | $38.07M | $25.55M | $17.73M | $10.20M | $2.92M | – | – | – | 24.6% | +49.0% |
| APONVIE | $11.57M | $4.52M | $1.39M | – | – | – | – | – | 7.5% | +156.1% |
| SUSTOL | $8.50M | $14.14M | $13.06M | $10.23M | $9.92M | $823.00K | $13.81M | $21.30M | 5.5% | -39.9% |
By region
From the segment and revenue-disaggregation notes of Heron Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.